Carl J. Lavie, MD, FACC, FACP, FCCP

Similar documents
2/11/2017. Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox. Disclosures. Carl J. Lavie, MD, FACC, FACP, FCCP

THE OBESITY PARADOX: IS IT ALL ABOUT CARDIOVASCULAR FITNESS?

2/11/2017. The Role of Exercise in Weight Loss and Maintanence. Disclosures

Title: Impact of Obesity on the Prevalence and Prognosis in Heart Failure It is Not Always Just Black and White

Obesity in the pathogenesis of chronic disease

Prof. Samir Morcos Rafla Alexandria Univ. Cardiology Dept.

Carl J. Lavie, Abhishek Sharma, Martin A. Alpert, Alban De Schutter, Francisco Lopez-Jimenez, Richard V. Milani, Hector O. Ventura

Dr.Kamal Waheeb AlGhalayini MD, SCC Med. MSc-Card Associate professor, Consultant Cardiology. Head non-invasive lab. Vice dean for clinical affaires

Obesity and Prevalence of Cardiovascular Diseases and Prognosis the Obesity Paradox Updated

Weighing in on obesity prevention and cardiovascular disease prognosis

Metabolic Syndrome in Asians

Diabetes and the Heart

Psychological Factors and Cardiac Risk and Impact of Exercise Training Programs A Review of Ochsner Studies

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

Impact of Echocardiographic Left Ventricular Geometry on Clinical Prognosis

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES

Established Risk Factors for Coronary Heart Disease (CHD)

Cardiovascular Complications of Diabetes

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

Page 1. Disclosures. Background. No disclosures

Cedars Sinai Diabetes. Michael A. Weber

Co-Morbidities Associated with OSA

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

Risks and benefits of weight loss: challenges to obesity research

Supplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and

Know Your Number Aggregate Report Single Analysis Compared to National Averages

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Overweight and Obesity in Older Persons: Impact Upon Health and Mortality Outcomes

Roadmap. Diabetes and the Metabolic Syndrome in the Asian Population. Asian. subgroups 8.9. in U.S. (% of total

Modifiable Up-Stream Risk Factors:

LDL cholesterol and cardiovascular outcomes?

Fasting or non fasting?

Obesity and Hypertension, Heart Failure, and Coronary Heart Disease Risk Factor, Paradox, and Recommendations for Weight Loss

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?

Management of Cardiovascular Disease in Diabetes

Left Atrial Volume:?Physiologic Model for Cardiovascular Disease Risk.

DIABETES. A growing problem

Heart Failure and COPD: Common Partners, Common Problems. Nat Hawkins Liverpool Heart and Chest Hospital

Sleep Disordered Breathing and HH with Preserved Ejection Fraction:

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Diabetes Mellitus: A Cardiovascular Disease

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

Approach to Dyslipidemia among diabetic patients

OBESITY IN PRIMARY CARE

Dyslipidemia in women: Who should be treated and how?

Evaluation of Anthropometric Indices of Patients with Left Ventricle Dysfunction Fallowing First Acute Anterior Myocardial Infarction

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium

Heart Failure and Sleep Disordered Breathing (SDB) Unhappy Bedfellows

Metabolic Syndrome.

Cardiovascular Disease After Spinal Cord Injury: Achieving Best Practice. Suzanne Groah, MD, MSPH Walter Reed Army Medical Center February 12, 2010

Controversies in Preventative Cardiology

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah

«Πατσζαρκία και Καρδιαγγειακή Νόζος»

The Clinical Unmet need in the patient with Diabetes and ACS

Consensus document: Screening and Prevention of Atrial Fibrillation

Risk Factors for Heart Disease

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Estrogens vs Testosterone for cardiovascular health and longevity

No relevant financial relationships

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Myths, Heart Disease and the Latino Population. Maria T. Vivaldi MD MGH Women s Heart Health Program. Hispanics constitute 16.3 % of US population!

CVD Prevention, Who to Consider

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Director, Employee Health & Productivity. Coordinator, Employee Health & Productivity

Sleep Apnea and Heart Failure

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

The role of physical activity in the prevention and management of hypertension and obesity

Nutritional concerns of overweight / obese older persons. Gordon L Jensen, MD, PhD Dept Nutritional Sciences Penn State University

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

The Metabolic Syndrome: Is It A Valid Concept? YES

Sleep and the Heart. Physiologic Changes in Cardiovascular Parameters during Sleep

Sleep and the Heart. Rami N. Khayat, MD

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center

Clinical Recommendations: Patients with Periodontitis

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

Guidelines on cardiovascular risk assessment and management

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Sleep Apnea: Vascular and Metabolic Complications

CARDIOMETABOLIC SYNDROME

The target blood pressure in patients with diabetes is <130 mm Hg

WAIST-HEIGHT RATIO : A NEW OBESITY INDEX FOR FILIPINOS?

Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study

Sleep Apnea induced Endothelial Dysfunction: could it be reversible?

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center

ADHD and Adverse Health Outcomes in Adults

Inflammation as A Target for Therapy. Focus on Residual Inflammatory Risk

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care

Editorial. Future Cardiology. ...the current body of evidence strongly suggests excess bodyweight is protective in patients with heart failure...

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon

Why Do We Treat Obesity? Epidemiology

Decline in CV-Mortality

Transcription:

Untangling the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox Carl J. Lavie, MD, FACC, FACP, FCCP Professor of Medicine Medical Director, Cardiac Rehabilitation and Preventive Cardiology Director, Exercise Laboratories John Ochsner Heart and Vascular Institute Ochsner Clinical School-The UQ School of Medicine New Orleans, La 1

Obesity and Cardiovascular Diseases Obesity increasing in epidemic proportions Body mass index (BMI) is primarily used Body fatness, waist circumference (WC), waist to hip ratio (WHR), and waist to height ratio may be superior Lavie CJ et al. JACC 2009;53:1925-1932 2

Obesity and Cardiovascular Diseases 70% of adults in US are overweight or obese Morbid obesity especially increased Obesity is second to only tobacco abuse as the #1 cause of preventable death in US Due to obesity, we may soon see a reversal e in the steady increase in life expectancy Lavie CJ et al. JACC 2009;53:1925-1932 3

Adverse Effects of Obesity Increases in insulin resistance Glucose intolerance Metabolic Syndrome Type 2 Diabetes Mellitus Hypertension Abnormal LV Geometry Concentric Remodeling LVH Lavie CJ et al. JACC 2009;53:1925-1932 4

Adverse Effects of Obesity DYSLIPIDEMIA Elevated total cholesterol Elevated VLDL and triglycerides Elevated LDL and small, dense particles Elevated non-hdl Elevated apolipoprotein B Reduced HDL and apolipoprotein A-1 Lavie CJ et al. JACC 2009;53:1925-1932 5

Adverse Effects of Obesity Abnormal endothelial l function Abnormal systolic and diastolic LV function Increased systemic inflammation (eg CRP) Increased Pro-thrombotic state Albuminuria Obstructive sleep apnea / sleep disordered breathing Lavie CJ et al. JACC 2009;53:1925-1932 6

Cardiovascular Diseases Associated With Obesity Hypertension Heart Failure Coronary Heart Disease Atrial Fibrillation Complex Ventricular Dysrhythmias Stroke Venous Thromboembolism OSA / SDB Lavie CJ et al. JACC 2009;53:1925-1932 7

Obesity and CV Disease 8

Higher BMI Risk of Development of Mortality in the General Population Relative Risk of Dea ath 1.8 1.6 1.4 1.2 1 0.8 06 0.6 0.4 BMI Associated Death Risk: General Population General Population BMI, kg/m 2 Calle et al, N Engl J Med 341:1097-1105 9

Meta-Analysis of BMI and Survival 97 studies,2.88 million individuals,>270,000 id 000 deaths Relative to normal weight, obesity(all grades combined) and grades 2 and 3 obesity were associated with higher all-cause mortality Grade 1 obesity was associated with a trend for lower mortality(hr 0.95;CI 0.88-1.01), and overweight had significantly lower mortality(hr 0.94;CI 0.91-0.96) Flegal KM et al.jama 2013;309(1):71-82 10

Obesity Paradox and Cardiovascular Diseases Although obesity has been implicated as one of the major risk factors for most CV diseases, including HTN, HF, and CHD, evidence from clinical cohorts of patients with established CV diseases indicates an obesity paradox because overweight and obese with these diseases tend to have a more favorable shortand long-term prognosis. Lavie CJ et al. JACC 2009;53:1925-1932 11

Obesity and Hypertension Obesity increases levels of BP Obesity increases CR and LVH, independent of BP Obesity increases metabolic abnormalities in HTN Despite the increased prevalence, obese hypertensives have a favorable prognosis Lavie CJ et al. JACC 2009;53:1925-1932 12

13

Obesity Paradox and Hypertension In aggregate, although obesity is a powerful risk factor for hypertension and LVH, obese hypertensive patients may paradoxically have a better prognosis, possibly due to low SVR and PRA Lavie CJ et al. JACC 2009;53:1925-1932 14

15

16

Obesity Status and Heart Failure Mortality Meta-Analysis of 9 Observational Studies Oreopoulos et al. Am Heart J 2008. The message from >28,000 CHF patients: Once you have heart failure, bigger = live longer 17

BMI and HF Hospital Mortality 108,927 decompensated HF patients Higher BMI associated with lower mortality For every 5-unit increase in BMI, HF mortality was 10 % lower (p < 0.001) Fonarow GC et al. Am Heart J 2007;153:74-81 18

19

Possible Reasons for Obesity Paradox in Heart Failure Advanced HF is catabolic state; obese may have more metabolic reserve Adipose tissue produces TNF-α α receptors that may neutralize TNF-α Obese have lower ANP and PRA Obese have higher BP, so may tolerate more meds Higher circulating lipoproteins i may detoxify lipopolysaccharides that effect inflammatory cytokines Lavie CJ et al. JACC 2009;53:1925-1932 20

Obesity and CHD Obesity adversely effects most major CV risk factors (HTN, dyslipidemia, MetS/T2DM) Obesity probably an independent CHD risk factor Obesity strongly related with 1 st premature MI at young age (Mandala MC et al. JACC 2008;52:979-985) Lavie CJ et al. JACC 2009;53:1925-1932 21

Obesity Paradox and CHD 40 cohort studies of over 250,000 CHD patients followed for 3.8 years Overweight and obese had lower risk of total and CV mortality compared with underweight and normal weight patients Similar in stable CHD, PCI and CABG In BMI 35 kg/m 2, there was excess risk of CV mortality without an increase on total mortality Romero-Corral A, et al. Lancet 2006; 368:666-678 22

Obesity Paradox and CHD 529 consecutive CHD patients post events Overweight and obese (n = 393) had more adverse CHD risk profiles than leaner patients t (n = 136) During 3-year follow-up, overweight/obese had significantly lower mortality Lavie CJ, et al. Am J Med 2009;122:1106-1114 23

Obesity Paradox and CHD Lavie CJ et al. Am J Med 2009;122:1106-1114 24

Obesity Paradox and CHD A. Low BMI B..20.20 Low Fat.15.15 rd ative Hazar Cumula.10.05 p<0.001 High BMI rd ative Hazar Cumula.10.05 p<0.01 High Fat 0 0 0 500 1000 1500 2000 0 500 1000 1500 2000 Time (Days) Time (Days) Lavie CJ et al. Am J Med 2009;122:1106-1114 25

Obesity Paradox and CHD Lavie CJ et al. Am J Med 2009;122:1106-1114 26

Lavie CJ et al. Mayo Clin Proc 2011;86(9):857-864. 27

The "Obesity Paradox" in CHD Lavie CJ et al. Mayo Clinic Proc 2011;86(9): 857-864 28

2/27/2013 The "Obesity Paradox" in CHD *p<0.0001 compared to other group Lavie CJ et al. Mayo Clinic Proc 2011;86(9): 857-864 29

Body Composition and CHD Mortality De Schutter A, Lavie CJ et al. Am J Cardiol, online December,2012 30

Lavie CJ et al. JACC 2012;60: 1374-1380. 31

Lean Mass Index and CHD Mortality Lavie CJ et al. JACC 2012;60: 1374-1380 32

Body Fat, Lean Mass Index and CHD Mortality Lavie CJ et al. JACC 2012; 60: 1374-1380 33

Obesity Paradox and CHD Mechanisms None of the studies accounted for nonpurposeful weight loss Lower renin and ANP in obese Confounders COPD Impact of Fitness Baseline genetic differences Lavie CJ, et al. Mayo Clin Proc 2011,86(9): 857-864 34

Obesity Paradox and CHD Impact of Central Obesity and Fitness Mayo Clinic Studies with No Obesity Paradox in CHD with Central Obesity:1) Goel K et al.am Heart J 2011;16(3):590-597 and 2)Coutinho T et al. JACC 2011;57(19): 1877-1886 UCLA HF Studies with Strong Obesity Paradox with Central Obesity:1) Clark AL et al. J Cardiac Failure 2011;17:374-380 and 2) Clark AL et al. Am J Cardiol 2012;110:77-82 Obesity Paradox in Central Obesity only with Low Fitness: McAuley PA et al.mayo Clin Proc 2012;87(5):443-451 451 35

McAuley PA, et al, Mayo Clin Proc 2012;87(5):483-451 36

Impact of Fitness on All-Cause Mortality in CHD BMI Waist Circumference % Body Fat McAuley PA, et al, Mayo Clin Proc 2012;87(5):483-451 37

Impact of Fitness on CVD Mortality in CHD BMI Waist Circumference % Body Fat McAuley PA, et al, Mayo Clin Proc 2012;87(5):483-451 38

Obesity Paradox and CVD Impact of CardiorespiratoryFitness Goel K et al.am Heart J 2011;16(3):590-597 McAuley PA et al.mayo Clin Proc 2010;85(2):115-121 McAuley PA et al.mayo Clin Proc 2012;87(5):443-451 451 Lavie CJ et al. Circulation 2012;Nov, in press 39

Obesity and Mortality Baseline Characteristics (n=35,607) Age 60 ± 15 years Gender 53% female BMI 29.2 ± 6.7 kg/m 2 EF 60 ± 5 % LVMI 82 ± 32 g/m 2 RWT 0.43 ± 0.07 Lavie CJ et al; Am J Cardiol 2007;100:1460-1464 40

LV Geometry and Obese Mortality Mort tality (% %) 9 * p<0.0001 8 7 6 5 4 3 2 1 0 3.9 Obese 7.8* Non-Obese Lavie CJ et al; Am J Cardiol 2007;100:1460-1464 41

BMI and Mortality 20 17.9 %) tality (% ar Mort 3-Yea 16 12 8 4 8 5 3.9 4 0 BMI Category: <18.5 18.5-25 25-30 30-3535 35 Mean: 17.0±1 22.5±1 27.4±1 32.1±1 40.6±5 N= 4 511 79,857 4 13,450 4 6,788 6 5,004 Lavie CJ et al;am J Cardiol 2007;100:1460-1464 42

Obesity and Mortality Multivariate Analysis (n= 35,607) Parameter Chi-Square P-value Higher age 785 <0.0001 Lower BMI 32.6 <0.0001 Male gender 10.3 = 0.00130013 Higher RWT 7.6 = 0.0006 Lavie CJ et al;am J Cardiol 2007;100:1460-1464 43

LV Geometry and Obese Mortality Multivariate Predictors of Mortality (n=11,792) Parameter aa ee Higher age Higher RWT High BMI Higher LVMI Male gender Chi-Square 198 22.0 14.4 13.5 89 8.9 P-Value aue <0.0001 <0.0001 =0.0001 =0.0002 =0.0303 Lavie CJ et al;am J Cardiol 2007;100:1460-1464 44

Mortality Prevalence by BMI Categories in Females 20 17.6 Mor rtality (%) 15 10 5 9.6 7.2 54 5.4 5.8 0 BMI Category <18.5 18.5-25 25-30 30-35 35 Mean 17.1 ± 27.4 ± 22.4 ± 32.3 ± 1.4 41.1 ± N 1.550 1.4 7532 1.7579 5044 6.3 5421 Patel D,Lavie CJ et al. Circulation 2008;118(18):S1153 45

Mortality in Four LV Geometric Patterns in Females with Preserved Systolic Function Morta ality (% %) 20 Non- obese Obese 15 10 5 *P<0.00010001 compared with normal **P<0.01 compared to CR P<0.0001, non-obese vs. obese * * 12.3 * * 7.2 72 5.6 * 2.2 ** 12.7 * ** 7.8 * 18.6 * 11.2 0 Normal CR EH CH Patel D,Lavie CJ et al. Circulation 2008;118(18):S1153 46

Obesity and Atrial Fibrillation As with obesity, AF is also epidemic, and is expected to increase by 2.5-fold by 2050 May be due to HTN, CHD, and HF Obesity appears to be a significant AF risk factor In a meta-analysis of 16 studies of 125,000 subjects, obesity increased the risk of AF by 49% (Wanahita N, Messerli FH et al. Am Heart J 2008;155: 310-315.) Lavie CJ, et al. JACC 2009;53:1925-1932 47

Obesity Paradox in Atrial Fibrillation ARRIRM Study (n=4,060) Badheka AO et al. Am J Med 2010;123:646-651. 48

Obesity Paradox in Atrial Fibrillation ARRIRM Study (n=4,060) Badheka AO et al. Am J Med 2010;123:646-651. 49

Obesity Paradox in Atrial Fibrillation ARRIRM Study (n=4,060) Badheka AO et al. Am J Med 2010;123:646-651. 50

Weight Loss in CV Diseases Obesity increases most CV risk factors and CV diseases However, an obesity paradox is present Weight loss improves risk factors Impact of weight loss on CV events remains controversial Artham SM, Lavie CJ, et al. Curr Treatment Options in CV Med 2010;12:21-35 51

Potential Adverse Effects of Weight Loss Obesity Paradox Prolonged QTc and increased ventricular dysrhythmias (starvation, very low calorie, liquid protein diets, and obesity surgeries) Pharmacologic agents have limited efficacy and considerable toxicity Lavie CJ, et al. JACC 2009;53:1925-1932 52

Weight Loss and Lifestyle Modifications Calorie restriction and exercise training is safe and is associated with 60% reduction in development of T2DM Knowler WL et al. NEJM 2002;346:393-403 Tuomilehto J, et al. NEJM 2001;344:1343-1350 CRET reduces MS by 37% Milani RV, Lavie CJ. AJC 2003;92:50-5454 In 1,500 CHD patients, 6 month weight loss programs associated with lower CHD events in 4 years Eilat-Adar S, et al. Am J Epidemiology 2005;161:352-358358 In 377 patients at Mayo Clinic, weight loss, even in those with BMI < 25 kg/m 2, was associated with reduced mortality/cv events Sierra-Johnson J et al. Eur CV Prev Rehabil 2008;15:336-340 53

Weight Loss in CV Diseases In HTN, weight loss reduces BP and LVH In HF, weight loss improves LVM, systolic and diastolic LV function, and functional class Obesity surgery improves CHD risk factors, T2DM, and short- and long-term mortality Obesity surgery in small studies is safe in CHD and HF Lavie CJ, et al. JACC 2009;53:1925-1932 54

Obesity, HF and Weight Loss Guideline Statements American Heart Association 40 kg/m 2 Heart Failure Society of America 35 kg/m 2 European Society of Cardiology 30 kg/m 2 Canadian Cardiovascular Society 30 kg/m 2 Vastly different cut-points due to minimal data by which to base these exact recommendations Clearly further research is needed to determine ideal BMI and body composition in CVD, including systolic and diastolic HF 55

Obesity and CV Diseases Summary and Conclusions Overwhelming evidence supports the importance of obesity in the pathogenesis and progression of most CV diseases An Obesity Paradox exists At present, evidence supports purposeful weight reduction If the current obesity epidemic continues, we may soon witness and unfortunate end to the steady increase in life expectancy Lavie CJ, et al. JACC 2009;53:1925-1932 56

Untangling the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox Carl J. Lavie, MD, FACC, FACP, FCCP Professor of Medicine Medical Director, Cardiac Rehabilitation and Preventive Cardiology Director, Exercise Laboratories John Ochsner Heart and Vascular Institute Ochsner Clinical School-The UQ School of Medicine New Orleans, LA 57